Drug intelligence / Profile preview

ANT058

Development stage: Preclinical
Lead developer: Cambium Oncology
Modality: Small Molecules

Overview

ANT058 is a preclinical-stage small molecule drug candidate being developed by Cambium Oncology. It is designed to target the Vasoactive Intestinal Peptide (VIP) and its associated receptors (VPAC1 and VPAC2), collectively referred to as the VIP/VPAC axis. This axis functions as a neuroimmune checkpoint that tumors often exploit to create an immunosuppressive microenvironment. By antagonizing these receptors, ANT058 aims to restore immune surveillance and enhance the anti-tumor activity of the immune system. The drug is currently being investigated for the treatment of hematologic malignancies, specifically Acute Myeloid Leukemia (AML).

Targets

VIPR1 (Vasoactive intestinal peptide receptor 1)VIPR2 (Vasoactive intestinal polypeptide receptor 2)

Beyond the preview

Go deeper on ANT058.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANT058.

Explore the full profile